NASDAQ:OABI

OmniAb (OABI) Stock Forecast, Price & News

$4.25

+0.08 (+1.92%)

(As of 05/26/2023 04:00 PM ET)

Compare

Today's Range: $4.13
▼
$4.27
50-Day Range: $3.21
▼
$4.31
52-Week Range: $1.91
▼
$10.50

Volume: 279,000 shs
Average Volume: 639,582 shs
Market Capitalization: $491.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

OmniAb MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 135.3% Upside
$10.00 Price Target
Short Interest: Bearish
4.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.53
Based on 4 Articles This Week
Insider Trading: Selling Shares
$230,950 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.37) to ($0.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

803rd out of 1,010 stocks

Commercial Physical Research Industry

14th out of 16 stocks

3.5

Analyst's Opinion

Consensus Rating
OmniAb has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, OmniAb has a forecasted upside of 135.3% from its current price of $4.25.
Amount of Analyst Coverage
OmniAb has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.64% of the float of OmniAb has been sold short.
Short Interest Ratio / Days to Cover
OmniAb has a short interest ratio ("days to cover") of 6.4.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
OmniAb does not currently pay a dividend.
Dividend Growth
OmniAb does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OABI.

2.0

News and Social Media Coverage

News Sentiment
OmniAb has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for OmniAb this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for OABI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OmniAb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $230,950.00 in company stock.
Percentage Held by Institutions
42.34% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for OmniAb are expected to decrease in the coming year, from ($0.37) to ($0.38) per share.
Price to Book Value per Share Ratio
OmniAb has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

OABI Stock News Headlines

May 28, 2023 | americanbankingnews.com

Insider Selling: OmniAb, Inc. (NASDAQ:OABI) Director Sells $36,450.00 in Stock

May 25, 2023 | americanbankingnews.com

OmniAb (NASDAQ:OABI) Trading 9% Higher

May 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

May 21, 2023 | americanbankingnews.com

John L. Higgins Sells 50,000 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

May 17, 2023 | finance.yahoo.com

OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo

May 16, 2023 | finance.yahoo.com

President of OmniAb Matthew Foehr Buys 22% More Shares \

May 15, 2023 | markets.businessinsider.com

SVB Securities Remains a Buy on OmniAb (OABI)

May 14, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially

May 29, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

May 13, 2023 | msn.com

Benchmark Reiterates OmniAb (OABI) Buy Recommendation

May 11, 2023 | finance.yahoo.com

OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

May 11, 2023 | americanbankingnews.com

OmniAb, Inc. (NASDAQ:OABI) Receives $10.00 Consensus PT from Brokerages

May 9, 2023 | americanbankingnews.com

OmniAb (OABI) Scheduled to Post Earnings on Thursday

May 5, 2023 | finance.yahoo.com

OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion

May 5, 2023 | americanbankingnews.com

Head-To-Head Review: Data Knights Acquisition (NASDAQ:DKDCA) and OmniAb (NASDAQ:OABI)

May 1, 2023 | finance.yahoo.com

OmniAb to Report First Quarter 2023 Financial Results on May 11

April 30, 2023 | americanbankingnews.com

Head-To-Head Contrast: OmniAb (NASDAQ:OABI) vs. MaxCyte (NASDAQ:MXCT)

April 25, 2023 | finance.yahoo.com

OmniAb to Participate in Upcoming Investor Conferences in May

April 24, 2023 | americanbankingnews.com

OmniAb (NASDAQ:OABI) Coverage Initiated by Analysts at Benchmark

April 21, 2023 | msn.com

Benchmark Initiates Coverage of OmniAb (OABI) with Buy Recommendation

April 16, 2023 | americanbankingnews.com

Analyzing OmniAb (NASDAQ:OABI) and Medpace (NASDAQ:MEDP)

April 16, 2023 | americanbankingnews.com

Brokerages Set OmniAb, Inc. (NASDAQ:OABI) PT at $10.29

April 14, 2023 | msn.com

Craig-Hallum Initiates Coverage of OmniAb (OABI) with Buy Recommendation

April 14, 2023 | americanbankingnews.com

OmniAb (NASDAQ:OABI) Earns Buy Rating from Analysts at Craig Hallum

April 10, 2023 | americanbankingnews.com

Analyzing MaxCyte (NASDAQ:MXCT) and OmniAb (NASDAQ:OABI)

April 8, 2023 | finance.yahoo.com

OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript

April 5, 2023 | finance.yahoo.com

OmniAb Full Year 2022 Earnings: Beats Expectations

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

OABI Company Calendar

Last Earnings: 3/30/2023
Today: 5/29/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OABI
CUSIP: N/A
CIK: 1846253
Web: www.omniab.com
Phone: 510-250-7800
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +135.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,330,000.00
Net Margins: N/A
Pretax Margin: -47.77%
Return on Equity: -1.76%
Return on Assets: -0.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.59
Quick Ratio: 5.59

Sales & Book Value

Annual Sales: $59.08 million
Price / Sales: 8.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.96 per share
Price / Book: 1.44

Miscellaneous

Outstanding Shares: 115,600,000
Free Float: N/A
Market Cap: $491.30 million
Optionable: Not Optionable
Beta: -0.88

Key Executives

Mr. Matthew W. Foehr (Age 50)
Pres, CEO & Director
Comp: $909k

Mr. Charles S. Berkman J.D. (Age 54)
Chief Legal Officer & Sec.
Comp: $665.83k

Mr. Kurt A. Gustafson (Age 55)
Exec. VP of Fin. & CFO

Dr. Bill Harriman Ph.D.
Sr. VP of Antibody Discovery

Ms. Marie-Cecile van de Lavoir D.V.M.
Ph.D., Sr. VP of Technical Operations & Genetics

Dr. Christel Iffland Ph.D.
Sr. VP of Antibody Technologies

Dr. Douglas S. Krafte Ph.D. (Age 65)
Sr. VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head

Ms. Donna Ventura CPA
Sr. VP of Corp. Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OABI Stock - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OABI shares.
View OABI analyst ratings or view top-rated stocks.
What is OmniAb's stock price forecast for 2023?: 9 brokerages have issued 1 year price targets for OmniAb's stock. Their OABI share price forecasts range from $6.00 to $13.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price.
View analysts price targets for OABI or view top-rated stocks among Wall Street analysts.
How have OABI shares performed in 2023?: OmniAb's stock was trading at $3.60 at the beginning of 2023. Since then, OABI shares have increased by 18.1% and is now trading at $4.25.
View the best growth stocks for 2023 here.
When is OmniAb's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our OABI earnings forecast.
How were OmniAb's earnings last quarter?: OmniAb, Inc. (NASDAQ:OABI) posted its quarterly earnings results on Thursday, March, 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. The firm had revenue of $35.35 million for the quarter, compared to the consensus estimate of $24.73 million.
What ETF holds OmniAb's stock ?: First Trust Multi-Manager Small Cap Opportunities ETF holds 299 shares of OABI stock, representing 0.04% of its portfolio.

What is OmniAb's stock symbol?: OmniAb trades on the NASDAQ under the ticker symbol "OABI."
Who are OmniAb's major shareholders?: OmniAb's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.94%), Macquarie Group Ltd. (3.27%), First Sabrepoint Capital Management LP (2.77%), Rice Hall James & Associates LLC (2.44%), William Blair Investment Management LLC (2.38%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends.
How do I buy shares of OmniAb?: Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is OmniAb's stock price today?: One share of OABI stock can currently be purchased for approximately $4.25.
How much money does OmniAb make?: OmniAb (NASDAQ:OABI) has a market capitalization of $491.30 million and generates $59.08 million in revenue each year.
How can I contact OmniAb?: OmniAb's mailing address is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.omniab.com. The company can be reached via phone at 510-250-7800 or via email at investors@omniab.com.

This page (NASDAQ:OABI) was last updated on 5/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial